Drug Substance Manufacturing for Viral Vaccines, Gene & Immune Therapeutics, Oncolytic Viruses and Viral Vectors

Drug Substance Manufacturing for Viral Vaccines, Gene & Immune Therapeutics, Oncolytic Viruses and Viral Vectors

Products
Drug Substance Manufacturing for Viral Vaccines, Gene & Immune Therapeutics, Oncolytic Viruses and Viral Vectors
Drug Substance Manufacturing for Viral Vaccines, Gene & Immune Therapeutics, Oncolytic Viruses and Viral Vectors

Information

Drug Substance Manufacturing for pre-clinical, clinical and commercial supply- Validation of aseptic processes - Cell and virus banking - Using own seed cell banks: VERO and DF-1, Duck cell line (AGE-1) - API production using different TechnologiesMVA Know-How IDT Biologika is considered the global leader in MVA (Modified Vaccinia Ankara) and recombinant and non-recombinant poxvirus technologies and aseptic processing Contact us for more information
Main Categories
APIs (Active Pharmaceutical Ingredients)BiopharmaceuticalsContract Services - Analytical & Lab Services
All Categories
APIs (Active Pharmaceutical Ingredients)BiopharmaceuticalsCell & Gene therapyContract Services - Analytical & Lab ServicesSera and Vaccines
Distribution areas
North America (USA, Canada)East Asia (e.g. China, Japan, Korea)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
Supplied from
United States
IDT Biologika GmbHIDT Biologika is a global biopharmaceutical contract development and manufacturing organization that specializes in the production of innovative live viral vaccines, viral vectors for gene & immune therapeutics, oncolytic viruses, virus-like particles as well as fill/finish of other sterile liquid and lyophilized biologics to improve human health worldwide. We offer clients in B2B business a single source CDMO partner at our sites in Germany and the USA, with seamless end-to-end solutions and the ability to nimbly scale projects from development through to commercialization. This includes process development, drug substance manufacturing,Fill/Finish, secondary packaging, quality control/analytics and storage. IDT Biologika handles every step in manufacturing and packaging of small clinical batches as well as of products in a large-scale commercial scale. On request of our clients we supply their products in vials, pre-filled syringes (with and without safety devices), autoinjectors or as combination products. In Rockville, MA, USA we utilize broad capabilities and a depth of technologies for process development and manufacturing of clinical trial material for phases I-II. At its headquarters in Europe, IDT Biologika operates one of Europe's premiere integrated facilities for end-to-end services from process development through clinical phases I-III to commercial manufacturing. Our fully integrated services are underscored by our commitment to quality and operational excellence that flows through our best-in-class process and cGMP (up to BSL2) manufacturing capabilities meeting EMA and FDA standards (ANVISA ready). Many human vaccines developed by IDT Biologika, together with international partners, are already in use, fighting infectious diseases such as COVID-19 Tuberculosis, AIDS, Malaria, Cancer, Dengue and Ebola.

Log in

See all the content and easy-to-use features by logging in or registering!